Recent News

• 02.07.2025 - Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 02.07.2025 - Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 01.31.2025 - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
• 01.31.2025 - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
• 01.31.2025 - Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
• 11.21.2024 - Iterum Therapeutics Regains Full Nasdaq Compliance
• 11.21.2024 - Iterum Therapeutics Regains Full Nasdaq Compliance
• 11.14.2024 - Iterum Therapeutics Reports Third Quarter 2024 Financial Results
• 11.14.2024 - Iterum Therapeutics Reports Third Quarter 2024 Financial Results
• 11.14.2024 - Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Recent Filings

• 02.07.2025 - EX-99.1 EX-99.1
• 02.07.2025 - 8-K Current report
• 02.07.2025 - S-3 Registration statement under Securities Act of 1933
• 02.07.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2024 - 8-K Current report
• 12.10.2024 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.21.2024 - EX-99.1 EX-99.1
• 11.21.2024 - 8-K Current report
• 11.14.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]